ELI LILLY AND COMPANY Sales Revenue, Goods, Net (Deprecated 2018-01-31)
ELI LILLY AND COMPANY (LLY) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $5.34 billion for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-04-27
- ELI LILLY AND COMPANY sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $5.34B, a 7.09% increase year-over-year.
- ELI LILLY AND COMPANY sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $4.99B.
- ELI LILLY AND COMPANY sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2013-09-30 was $5.59B, a 5.43% increase year-over-year.
- ELI LILLY AND COMPANY sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2013-06-30 was $5.76B, a 5.58% increase year-over-year.
- ELI LILLY AND COMPANY sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2012 was $21.97B, a 6.92% decline from fiscal 2011.
- ELI LILLY AND COMPANY sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2011 was $23.60B, a 5.18% increase from fiscal 2010.
- ELI LILLY AND COMPANY sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2010 was $22.44B, a 6.00% increase from fiscal 2009.
- ELI LILLY AND COMPANY sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2009 was $21.17B, a 6.25% increase from fiscal 2008.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $5.34B 10-Q · filed 2018-04-27 | |||
| 2017-03-31 | $4.99B 10-Q · filed 2018-04-27 | |||
| 2013-09-30 | $5.59B 10-Q · filed 2013-10-30 | $11.35B derived: sum of 2 quarters · filed 2013-10-30 | $16.80B 10-Q · filed 2013-10-30 | $22.60B derived: sum of 4 quarters · filed 2013-10-30 |
| 2013-06-30 | $5.76B 10-Q · filed 2013-07-26 | $11.21B 10-Q · filed 2013-07-26 | $17.01B derived: sum of 3 quarters · filed 2013-07-26 | $22.31B derived: sum of 4 quarters · filed 2013-10-30 |
| 2013-03-31 | $5.45B 10-Q · filed 2013-04-26 | $11.25B derived: sum of 2 quarters · filed 2013-04-26 | $16.55B derived: sum of 3 quarters · filed 2013-10-30 | $22.01B derived: sum of 4 quarters · filed 2013-10-30 |
| 2012-12-31 | $5.80B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $11.10B derived: sum of 2 quarters · filed 2013-10-30 | $16.56B derived: sum of 3 quarters · filed 2013-10-30 | $21.97B 10-K · filed 2013-02-21 |
| 2012-09-30 | $5.30B 10-Q · filed 2013-10-30 | $10.76B derived: sum of 2 quarters · filed 2013-10-30 | $16.17B 10-Q · filed 2013-10-30 | $22.03B derived: sum of 4 quarters · filed 2013-10-30 |
| 2012-06-30 | $5.46B 10-Q · filed 2013-07-26 | $10.87B 10-Q · filed 2013-07-26 | $16.73B derived: sum of 3 quarters · filed 2013-07-26 | $22.70B derived: sum of 4 quarters · filed 2013-07-26 |
| 2012-03-31 | $5.41B 10-Q · filed 2013-04-26 | $11.27B derived: sum of 2 quarters · filed 2013-04-26 | $17.24B derived: sum of 3 quarters · filed 2013-04-26 | $23.33B derived: sum of 4 quarters · filed 2013-04-26 |
| 2011-12-31 | $5.86B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $11.83B derived: sum of 2 quarters · filed 2013-02-21 | $17.91B derived: sum of 3 quarters · filed 2013-02-21 | $23.60B 10-K · filed 2013-02-21 |
| 2011-09-30 | $5.97B 10-Q · filed 2012-10-26 | $12.06B derived: sum of 2 quarters · filed 2012-10-26 | $17.75B 10-Q · filed 2012-10-26 | $23.78B derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $6.09B 10-Q · filed 2012-07-27 | $11.78B 10-Q · filed 2012-07-27 | $17.81B derived: sum of 3 quarters · filed 2013-02-21 | $23.30B derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | $5.69B 10-Q · filed 2012-04-30 | $11.72B derived: sum of 2 quarters · filed 2013-02-21 | $17.21B derived: sum of 3 quarters · filed 2013-02-21 | $22.80B derived: sum of 4 quarters · filed 2013-02-21 |
| 2010-12-31 | $6.03B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $11.52B derived: sum of 2 quarters · filed 2013-02-21 | $17.11B derived: sum of 3 quarters · filed 2013-02-21 | $22.44B 10-K · filed 2013-02-21 |
| 2010-09-30 | $5.49B 10-Q · filed 2011-10-28 | $11.08B derived: sum of 2 quarters · filed 2011-10-28 | $16.41B 10-Q · filed 2011-10-28 | $22.19B derived: sum of 4 quarters · filed 2012-02-24 |
| 2010-06-30 | $5.59B 10-Q · filed 2011-07-29 | $10.92B 10-Q · filed 2011-07-29 | $16.70B derived: sum of 3 quarters · filed 2012-02-24 | $22.09B derived: sum of 4 quarters · filed 2012-02-24 |
| 2010-03-31 | $5.33B 10-Q · filed 2011-04-29 | $11.11B derived: sum of 2 quarters · filed 2012-02-24 | $16.50B derived: sum of 3 quarters · filed 2012-02-24 | $21.61B derived: sum of 4 quarters · filed 2012-02-24 |
| 2009-12-31 | $5.78B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | $11.17B derived: sum of 2 quarters · filed 2012-02-24 | $16.28B derived: sum of 3 quarters · filed 2012-02-24 | $21.17B 10-K · filed 2012-02-24 |
| 2009-09-30 | $5.39B 10-Q · filed 2010-10-29 | $10.50B derived: sum of 2 quarters · filed 2010-10-29 | $15.39B 10-Q · filed 2010-10-29 | |
| 2009-06-30 | $5.11B 10-Q/A · filed 2010-08-02 | $10.01B 10-Q/A · filed 2010-08-02 | ||
| 2008-12-31 | $5.09B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-22 | $10.18B derived: sum of 2 quarters · filed 2011-02-22 | $15.22B derived: sum of 3 quarters · filed 2011-02-22 | $19.93B 10-K · filed 2011-02-22 |
| 2008-09-30 | $5.09B 10-Q · filed 2009-10-30 | $10.13B derived: sum of 2 quarters · filed 2009-10-30 | $14.84B 10-Q · filed 2009-10-30 | |
| 2008-06-30 | $5.03B 10-Q · filed 2009-07-31 | $9.74B 10-Q · filed 2009-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |